China actively develops high-tech such as biomedicine, and new developments in diabetes drugs

Pharmaceutical Network Industry Dynamics, influenced by diet and lifestyle, has continued to increase the incidence of diabetes in recent years, according to the eighth edition of the International Diabetes Alliance (IDF) global diabetes data, the number of people with diabetes in the world as high as 425 million, about 114 million patients in Chinait is understood that the Healthy China Initiative (2019-2030) lists diabetes as one of the four major chronic diseases that need to be targeted for prevention and controlto better treat diabetes, in recent years, drug research and development has also attracted the attention of the industry, at the same time, the sugar drug market is also constantly coming up with good newscurrently available in the global market for blood sugar reduction drugs, there are four main: insulin, DPPIV inhibitors, GLP-1 receptor agonists, SGLT2 inhibitorsinsulin is the main drug, second- and third-generation insulin accounts for 52% of the sugar-lowering drug market, DPPIV inhibitors account edifle 27%, GLP-1 accounted for 12%domestic market, insulin and oral sugar-lowering drugs (OAD) are still the dominant drugs in public hospitals in China, with insulin accounting for 52% and oral sugar-lowering drugs (OAD) accounting for 47%diabetes is a high incidence of diseases in the world, at present, scientists on the clinical research of diabetes is in constant development, from the traditional sugar-lowering drugs, insulin injections, to islet transplantation or pancreas transplantation, and then the emergence of molecular target drugs, stem cell therapy and other high-tech technologies, among which, stem cell therapy by the state's support and affirmation, clinical research progress is rapid, showing great potential for applicationit is understood that China attaches great importance to the clinical transformation of stem cell research, in a good scientific research atmosphere, China has made important results in the clinical study of stem cell therapy on diabetesas of June 2020, the U.SClinical Research Website has registered 121 clinical studies of stem cell therapy on diabetes, of which 41 have been completed and 8 have been studied in China, which also has won a seat in the field of international stem cells for China! For the development of diabetes drugs, many enterprises are also accelerating the development of research and developmentsuch as Hong Kong-listed Hualing Pharmaceuticals -B (02552.HK) announced that dorzagliatin (HMS5552) and metformin combined drugs of the key phase III registered clinical study (HMM0302) in a 24-week randomized, double-blind, placebo-controlled trial to achieve the main efficacy and safety endpoint, the trial in the metformin foot treatment failure of China's type 2 diabetes patients, the resultofastudy data showed that the HbA1c response rate, HOMA2-beta (beta cell function index) and HOMA2-IR (insulin resistance index) in the dorzagliatin treatment group all showed significant statistical lying improvements in the two hours after meals, and fasting blood sugar valuesit is known that Dorzagliatin is a globally functioning glucose kinase promoter designed to control the development of progressive degenerative diseases of diabetes by restoring the blood sugar steady state of people with type 2 diabetesby repairing defects in the function of glucose sensors of glucose kinase, dorzagliatin has the potential to restore impaired blood sugar steady state in patients with type 2 diabetes, which can be used as a first-line treatment standard for the disease or as a basis for combination with currently approved anti-diabetic drugsin addition, on May 12, the listed company Changshan Pharmaceuticals announced that the company and holding subsidiary Changshan Kaijiejian is responsible for the development of the treatment of type 2 diabetes long-acting GLP-1 receptor agonists preparation, 1.1 innovative drug Abenapeptide clinical phase III clinical clinical trial launched, marking the beginning of the pre-market sprint stage of Abena peptideit is understood that ebenapeptides are modified for eseninapeptides, combined with recombinant human albumin, and are a class 1.1 drug used to treat type 2 diabetesthe drug effectively solves the problem of glP-1 drug half-life is short, abena peptide half-life reached 7 days, so clinically can do patients only need to be injected once a week, can effectively reduce blood sugar, greatly enhance the ease of use of patients and more stable control of blood sugarbecause the drug uses recombinant human albumin technology, has good safety and tolerance, in the treatment of diabetes at the same time, can greatly improve the health of patientsin recent years, China's active development of bio-medical and other high-tech technologies, which is conducive to improve China's finishing of technical research level, master more key technologies, while with the continuous research and development of diabetes drugs, China's hundreds of millions of diabetics will usher in more hope!